LINFOMAS Y TRASPLANTES
![Foto de LINFOMAS Y TRASPLANTES](/img/grupo.png)
![Foto de Policlinico S.Orsola-Malpighi](/img/noimage_org.png)
Policlinico S.Orsola-Malpighi
Bolonia, ItaliaPoliclinico S.Orsola-Malpighi-ko ikertzaileekin lankidetzan egindako argitalpenak (6)
2023
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
Blood, Vol. 142, Núm. 2, pp. 141-145
-
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma
Journal of Clinical Oncology
2022
-
Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT
British Journal of Haematology, Vol. 196, Núm. 4, pp. 1018-1030
-
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
Blood Advances
-
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 242-251